UNI-MB - logo
UMNIK - logo
 
E-resources
Full text
Peer reviewed Open access
  • COVID-19 vaccine effectiven...
    Bijukchhe, Sanjeev M; O'Reilly, Peter J; Theiss-Nyland, Katherine; Gurung, Meeru; Pokhrel, Bhishma; Kelly, Sarah; Acharya, Samita; Maharjan, Shreekrishna; Shrestha, Ashis; Pandey, Bimal; Lama, Mipsang; Shrestha, Ira; Voysey, Merryn; Eordogh, Agnes; Shrestha, Sonu; Feng, Elaine Shuo; Li, Grace; Shah, Ganesh; Pollard, Andrew J; Shrestha, Shrijana

    BMJ open, 04/2023, Volume: 13, Issue: 4
    Journal Article

    IntroductionInactivated, viral vector and mRNA vaccines have been used in the Nepali COVID-19 vaccination programme but there is little evidence on the effectiveness of these vaccines in this setting. The aim of this study is to describe COVID-19 vaccine effectiveness in Nepal and provide information on infections with SARS-CoV-2 variants.Methods and analysisThis is a hospital-based, prospective test-negative case–control study conducted at Patan Hospital, Kathmandu. All patients >18 years of age presenting to Patan Hospital with COVID-19-like symptoms who have received a COVID-19 antigen/PCR test are eligible for inclusion. The primary outcome is vaccine effectiveness of licensed COVID-19 vaccines against laboratory-confirmed COVID-19 disease.After enrolment, information will be collected on vaccine status, date of vaccination, type of vaccine, demographics and other medical comorbidities. The primary outcome of interest is laboratory-confirmed SARS-CoV-2 infection. Cases (positive for SARS-CoV-2) and controls (negative for SARS-CoV-2) will be enrolled in a 1:4 ratio. Vaccine effectiveness against COVID-19 disease will be analysed by comparing vaccination status with SARS-CoV-2 test results.Positive SARS-CoV-2 samples will be sequenced to identify circulating variants and estimate vaccine effectiveness against common variants.Measuring vaccine effectiveness and identifying SARS-CoV-2 variants in Nepal will help to inform public health efforts. Describing disease severity in relation to specific SARS-CoV-2 variants and vaccine status will also inform future prevention and care efforts.Ethics and disseminationEthical approval was obtained from the University of Oxford Tropical Ethics Committee (OxTREC) (ref: 561-21) and the Patan Academy of Health Sciences Institutional Review Board (ref: drs2111121578). The protocol and supporting study documents were approved for use by the Nepal Health Research Council (NHRC 550-2021). Results will be disseminated in peer-reviewed journals and to the public health authorities in Nepal.